Pharming Group N.V.: Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
18.04.2024 - NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond .
CELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion
Erik Gatenholm, CEO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566
Phone (US): +1 (857) 332 2138
Email: eg@cellink.com
Email: gd@cellink.com
This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above at 01.30 CET on 12 March 2021.
About CELLINK
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to cult